EU Illumina/Grail ruling creates another regulatory hurdle for dealmakers

Lucy Frost

August 04, 2022

X
LinkedIn
Email
Show more sharing options

Illumina headquarters. Illumina is an American biotechnology company, - San Diego, California, USA - 2020

The acquisition did not trigger any regulatory filings within the EU due to Grail's lack of revenues, so the Commission turned to Article 22

Unlock this content.

The content you are trying to view is exclusive to our subscribers.

To unlock this content:

Take a Free Trial or Login

Topics

Lucy Frost

Reporter Euromoney

Lucy graduated from Oxford University and completed an NCTJ Diploma in Multimedia Journalism while interning at the Financial Times. She covers a wide range of areas including regulation, M&A and ESG. With a background in sustainability and financial journalism, she is particularly interested in the role of the private sector in the transition to net-zero.